Innocan Pharma (CSE: INNO) (FSE: IP4) is at the forefront of a revolutionary shift in pharmaceutical cannabinoids therapies. With the recent unveiling...
The year 2022 has been a difficult one for many companies. The tech sector is finding it difficult to gain traction amid...
InnoCan Pharma Corporation reported strong revenue growth for the first quarter that ended March 31, 2022, demonstrating the favorable operating conditions enjoyed...